Neoplasms

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Digestive System Diseases

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Adenocarcinoma

Neoplasm Metastasis

Uterine Cervical Neoplasms

Vaginal Neoplasms

Vulvar Neoplasms

Anus Neoplasms

Carcinoma, Adenosquamous

Squamous Cell Carcinoma of Head and Neck

Oropharyngeal Neoplasms

Penile Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Anus Diseases

Rectal Diseases

Head and Neck Neoplasms

Vaginal Diseases

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Genital Neoplasms, Male

Genital Diseases, Male

Penile Diseases

Male Urogenital Diseases

Vulvar Diseases

Vaginal Cancer

Penile Cancer

Anal Cancer

Vulvar Cancer

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Anti-Infective Agents

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Aldesleukin

Immunomodulating Agents

Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.

Participants will receive a conditioning regimen (cyclophosphamide and fludarabine), E7 TCR-T cells as a single infusion, and adjuvant high-dose aldesleukin.

E7 TCR-T cells

Carrie Snyder

Christian Hinrichs, MD

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

This study will determine the tumor response rate for the treatment of HPV-associated cancers with E7 TCR-T cells. E7 TCR-T cells are autologous gene-engineered T cells that target HPV16 E7 through a T cell receptor (TCR). E7 is an HPV oncoprotein that is present in HPV-associated cancers. Participants must have the HLA-A\*02:01 allele, which is required for tumor targeting by the E7 TCR. Treatment consists of a conditioning regimen (cyclophosphamide and fludarabine), a single infusion of E7 TCR-T cells, and adjuvant aldesleukin. Tumor response rate and response duration will be determined. Safety data will also be collected.

This is a single-arm phase II clinical trial.

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers

Primary and secondary endpoint data will be shared.

Objective tumor response as measured by RECIST

Christian Hinrichs

Chief, Section of Cancer Immunotherapy

Substance Related Disorders

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

dose escalation group: participants with advanced solid tumors using cryopreserved GC101 TIL

participants with advanced cervix tumors using cryopreserved GC101 TIL

participants with advanced malignant melanoma using cryopreserved GC101 TIL

participants with advanced HNSCC using cryopreserved GC101 TIL

A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.

TIL therapy

Mengmeng Tang

Jianming Xu

20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.

The Phase I clinical trial is expected to be finished in 36 months. To be specific, the dose escalation study plans to include patients with advanced malignant solid tumors with clear pathological diagnosis, including melanoma, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer and breast cancer, etc.; while the expanded enrollment study plans to include those with melanoma, cervical cancer, and head and neck squamous cell tumors.

A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors

An Open, Single-armed, Phase I Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Advanced Malignant Solid Tumors

Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST

Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST

Evaluate the efficacy endpoints of PFS by the investigator with RECIST v1.1 and iRECIST

Evaluate the efficacy endpoints of ORR by the investigator with RECIST v1.1 and iRECIST

Shanghai Juncell Therapeutics

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers	NCT05686226	Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re...	E7 TCR-T cells	18 Years -	Rutgers, The State University of New Jersey
A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors	NCT05417750	Tumor Infiltrat... Safety Advanced Solid ... Immunotherapy Efficacy Adverse Drug Ev...	TIL therapy	18 Years - 75 Years	Shanghai Juncell Therapeutics

Spots Global Cancer Trial Database for til therapy

Every month we try and update this database with for til therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for til therapy

Every month we try and update this database with for til therapy cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for til therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.